Get started
Author

Andrea Deabreu

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes
2013 · Andrew Loblaw, Patrick Cheung, et al. · Radiotherapy and Oncology · 165
Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Men With Intermediate-Risk Prostate Cancer: Analysis of Short- and Medium-Term Toxicity and Quality of Life
2009 · Gerard C. Morton, D. Andrew Loblaw, et al. · International Journal of Radiation Oncology*Biology*Physics · 99
Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
2011 · Gerard Morton, Andrew Loblaw, et al. · Radiotherapy and Oncology · 94
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
2018 · Harvey C. Quon, Aldrich Ong, et al. · Radiotherapy and Oncology · 81
Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life
2018 · Hima Bindu Musunuru, Laura D'Alimonte, et al. · International Journal of Radiation Oncology*Biology*Physics · 67
Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials
2016 · H Bindu Musunuru, Harvey Quon, et al. · Radiotherapy and Oncology · 67
Health-Related Quality of Life After Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Prostate Cancer
2010 · Gerard C. Morton, D. Andrew Loblaw, et al. · International Journal of Radiation Oncology*Biology*Physics · 66
High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success
2015 · Joelle Helou, Laura D’Alimonte, et al. · Radiotherapy and Oncology · 63
Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials
2018 · Yasir Alayed, Patrick Cheung, et al. · Radiotherapy and Oncology · 60
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation
2018 · Yasir Alayed, Patrick Cheung, et al. · International Journal of Radiation Oncology*Biology*Physics · 54
Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer
2017 · N. Shahid, A. Loblaw, et al. · Clinical Oncology · 54
Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer: Late Toxicity
2011 · Harvey Quon, Patrick C.F. Cheung, et al. · International Journal of Radiation Oncology*Biology*Physics · 50
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
2020 · Yasir Alayed, Harvey Quon, et al. · Radiotherapy and Oncology · 46
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer
2015 · Hima Bindu Musunuru, Melanie Davidson, et al. · International Journal of Radiation Oncology*Biology*Physics · 42
Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials
2020 · Yasir Alayed, Melanie Davidson, et al. · International Journal of Radiation Oncology*Biology*Physics · 38
Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy
2014 · Evelyn Elias, Joelle Helou, et al. · Radiotherapy and Oncology · 38
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion – Results from the 2SMART phase 2 trial
2023 · Wee Loon Ong, Patrick Cheung, et al. · Radiotherapy and Oncology · 35
Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?
2017 · Joelle Helou, Laura D'Alimonte, et al. · Radiotherapy and Oncology · 34
A phase I/II trial of oxidized autologous tumor vaccines during the “watch and wait” phase of chronic lymphocytic leukemia
2004 · David E. Spaner, Caitlin Hammond, et al. · Cancer Immunology Immunotherapy · 33
The effect of radiation technique and bladder filling on the acute toxicity of pelvic radiotherapy for localized high risk prostate cancer
2012 · Suneil Jain, D. Andrew Loblaw, et al. · Radiotherapy and Oncology · 31
Intra-fraction Motion during Extreme Hypofractionated Radiotherapy of the Prostate using Pre- and Post-treatment Imaging
2012 · H. Quon, D.A. Loblaw, et al. · Clinical Oncology · 31
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update
2024 · John M. Hudson, Andrew Loblaw, et al. · Radiotherapy and Oncology · 30
PDF
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy
2019 · Yasir Alayed, Melanie Davidson, et al. · Radiotherapy and Oncology · 26
Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT)
2014 · Adam Gladwish, Geordi Pang, et al. · Radiation Oncology · 23
PDF
Accelerated Hypofractioned Postoperative Radiotherapy for Prostate Cancer: A Prospective Phase I/II Study
2015 · A. Gladwish, A. Loblaw, et al. · Clinical Oncology · 22
Works count: 124
Citation count: 1,691
H-index: 23
I10-index: 41
Year
Topic
Type